UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/639,076	08/11/2003	Mark S. Dennis	P1639R1C1	6938

23552	7590	04/05/2006

MERCHANT & GOULD PC
P.O. BOX 2903
MINNEAPOLIS, MN 55402-0903

EXAMINER
ROBINSON, HOPE A

ART UNIT	PAPER NUMBER
1656	

DATE MAILED: 04/05/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 10/03)

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.

	EXAMINER

ART UNIT	PAPER
	033106

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The sequence listing filed on December 29, 2005 does not comply with the sequence rules see the attached error report and notice to comply.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR1.821 through 1.825; applicant's attention is directed to the final rule making notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). To be in compliance, applicant is required to identify all amino acid sequences of at least 4 L-amino acids and at least 10 nucleotides by a sequence identifier, i.e., "SEQ ID NO:". The sequence listing provided has errors therefore, applicant must provide a computer readable form of the "Sequence Listing" including these sequences, a paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable form copies are the same and, where applicable, include no new matter as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.821(b) or 1.825(d). See the attached Notice to Comply with the sequence rules.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hope A. Robinson whose telephone number is 571-272-0957. The examiner can normally be reached on Monday-Friday.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr, can be reached at (571) 272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Hope Robinson, MS
Patent Examiner
HOPE ROBINSON   3/30/06
PATENT EXAMINER

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: _10/639,076 A_
Source: _1 Fw/6_
Date Processed by STIC: _1/6/06_

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY
FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
   http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Raw Sequence Listing Error Summary

ERROR DETECTED **SUGGESTED CORRECTION** SERIAL NUMBER: *10/639,076A*

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1____Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line. This may occur if your file
Wrapped Aminos was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2____Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.

3____Misaligned Amino The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers;
Numbering use space characters, instead.

4____Non-ASCII The submitted file was not saved in ASCII(DOS) text, as **required** by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5 ✓____Variable Length *10, 103, 10 9* Sequence(s)____contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue.** Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6____PatentIn 2.0 A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
"bug" sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**

7____Skipped Sequences Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence:
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i)   SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8____Skipped Sequences Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
(NEW RULES) <210> sequence id number
<400> sequence id number
000

9____Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10____Invalid <213> Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or
Response scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence

11____Use of <220> Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12____PatentIn 2.0 Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file,
"bug" resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13____ Misuse of n/Xaa "n" can only represent a single <u>nucleotide</u>; "Xaa" can only represent a single <u>amino acid</u>

IFW16

RAW SEQUENCE LISTING   DATE: 01/06/2006
PATENT APPLICATION: US/10/639,076A   TIME: 12:49:49

Input Set : A:\Sequence Listing.txt
Output Set: N:\CRF4\01062006\J639076A.raw

```
 3 <110> APPLICANT: Dennis, Mark S.
 5 <120> TITLE OF INVENTION: FVIIA ANTAGONISTS
 7 <130> FILE REFERENCE: 11669.232USC1
 9 <140> CURRENT APPLICATION NUMBER: US 10/639,076A
10 <141> CURRENT FILING DATE: 2003-08-11
12 <150> PRIOR APPLICATION NUMBER: US 09/632,429
13 <151> PRIOR FILING DATE: 2000-08-04
15 <150> PRIOR APPLICATION NUMBER: US 60/147,627
16 <151> PRIOR FILING DATE: 1999-08-06
18 <150> PRIOR APPLICATION NUMBER: US 60/150,315
19 <151> PRIOR FILING DATE: 1999-08-23
21 <160> NUMBER OF SEQ ID NOS: 109
23 <170> SOFTWARE: PatentIn version 3.3
25 <210> SEQ ID NO: 1
26 <211> LENGTH: 20
27 <212> TYPE: PRT
28 <213> ORGANISM: Artificial Sequence
30 <220> FEATURE:
31 <223> OTHER INFORMATION: Synthetic peptide sequence
33 <400> SEQUENCE: 1
35 Ser Ala Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Gly Cys Gly Ser
36 1               5                   10                  15
39 Val Gly Leu Val
40              20
43 <210> SEQ ID NO: 2
44 <211> LENGTH: 20
45 <212> TYPE: PRT
46 <213> ORGANISM: Artificial Sequence
48 <220> FEATURE:
49 <223> OTHER INFORMATION: Synthetic peptide sequence
51 <400> SEQUENCE: 2
53 Ser Glu Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Asp Cys Arg Leu
54 1               5                   10                  15
57 Glu Gly Leu Glu
58              20
61 <210> SEQ ID NO: 3
62 <211> LENGTH: 13
63 <212> TYPE: PRT
64 <213> ORGANISM: Artificial Sequence
66 <220> FEATURE:
67 <223> OTHER INFORMATION: Synthetic peptide sequence
69 <400> SEQUENCE: 3
71 Trp Glu Val Leu Cys Trp Thr Trp Glu Asp Cys Glu Arg
```

RAW SEQUENCE LISTING   DATE: 01/06/2006
PATENT APPLICATION: US/10/639,076A   TIME: 12:49:49

Input Set : A:\Sequence Listing.txt
Output Set: N:\CRF4\01062006\J639076A.raw

72 1   5   10
75 <210> SEQ ID NO: 4
76 <211> LENGTH: 13
77 <212> TYPE: PRT
78 <213> ORGANISM: Artificial Sequence
80 <220> FEATURE:
81 <223> OTHER INFORMATION: Synthetic peptide sequence
83 <400> SEQUENCE: 4
85 Trp Glu Val Leu Cys Trp Thr Trp Glu Thr Cys Glu Arg
86 1   5   10
89 <210> SEQ ID NO: 5
90 <211> LENGTH: 13
91 <212> TYPE: PRT
92 <213> ORGANISM: Artificial Sequence
94 <220> FEATURE:
95 <223> OTHER INFORMATION: Synthetic peptide sequence
97 <400> SEQUENCE: 5
99 Trp Glu Val Val Cys Trp Thr Trp Glu Thr Cys Glu Arg
100 1   5   10
103 <210> SEQ ID NO: 6
104 <211> LENGTH: 15
105 <212> TYPE: PRT
106 <213> ORGANISM: Artificial Sequence
108 <220> FEATURE:
109 <223> OTHER INFORMATION: Synthetic peptide sequence
111 <400> SEQUENCE: 6
113 Ser Glu Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Asp Cys Arg
114 1   5   10   15
117 <210> SEQ ID NO: 7
118 <211> LENGTH: 14
119 <212> TYPE: PRT
120 <213> ORGANISM: Artificial Sequence
122 <220> FEATURE:
123 <223> OTHER INFORMATION: Synthetic peptide sequence
125 <400> SEQUENCE: 7
127 Glu Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Asp Cys Arg
128 1   5   10
131 <210> SEQ ID NO: 8
132 <211> LENGTH: 13
133 <212> TYPE: PRT
134 <213> ORGANISM: Artificial Sequence
136 <220> FEATURE:
137 <223> OTHER INFORMATION: Synthetic peptide sequence
139 <400> SEQUENCE: 8
141 Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Asp Cys Arg
142 1   5   10
145 <210> SEQ ID NO: 9
146 <211> LENGTH: 12
147 <212> TYPE: PRT

```
148 <213> ORGANISM: Artificial Sequence
150 <220> FEATURE:
151 <223> OTHER INFORMATION: Synthetic peptide sequence
153 <400> SEQUENCE: 9
155 Trp Glu Val Leu Cys Trp Thr Trp Glu Asp Cys Arg
156 1               5                   10
159 <210> SEQ ID NO: 10
160 <211> LENGTH: 11
161 <212> TYPE: PRT
162 <213> ORGANISM: Artificial Sequence
164 <220> FEATURE:
165 <223> OTHER INFORMATION: Synthetic peptide sequence
167 <400> SEQUENCE: 10
169 Glu Val Leu Cys Trp Thr Trp Glu Asp Cys Arg
170 1               5                   10
173 <210> SEQ ID NO: 11
174 <211> LENGTH: 10
175 <212> TYPE: PRT
176 <213> ORGANISM: Artificial Sequence
178 <220> FEATURE:
179 <223> OTHER INFORMATION: Synthetic peptide sequence
181 <400> SEQUENCE: 11
183 Val Leu Cys Trp Thr Trp Glu Asp Cys Arg
184 1               5                   10
187 <210> SEQ ID NO: 12
188 <211> LENGTH: 8
189 <212> TYPE: PRT
190 <213> ORGANISM: Artificial Sequence
192 <220> FEATURE:
193 <223> OTHER INFORMATION: Synthetic peptide sequence
195 <400> SEQUENCE: 12
197 Cys Trp Thr Trp Glu Asp Cys Arg
198 1               5
201 <210> SEQ ID NO: 13
202 <211> LENGTH: 9
203 <212> TYPE: PRT
204 <213> ORGANISM: Artificial Sequence
206 <220> FEATURE:
207 <223> OTHER INFORMATION: Synthetic peptide sequence
209 <400> SEQUENCE: 13
211 Cys Trp Thr Trp Glu Asp Cys Glu Arg
212 1               5
215 <210> SEQ ID NO: 14
216 <211> LENGTH: 8
217 <212> TYPE: PRT
218 <213> ORGANISM: Artificial Sequence
220 <220> FEATURE:
221 <223> OTHER INFORMATION: Synthetic peptide sequence
223 <400> SEQUENCE: 14
```

```
225 Cys Trp Thr Trp Glu Asp Cys Glu
226 1               5
229 <210> SEQ ID NO: 15
230 <211> LENGTH: 9
231 <212> TYPE: PRT
232 <213> ORGANISM: Artificial Sequence
234 <220> FEATURE:
235 <223> OTHER INFORMATION: Synthetic peptide sequence
237 <400> SEQUENCE: 15
239 Cys Trp Thr Trp Glu Thr Cys Glu Arg
240 1               5
243 <210> SEQ ID NO: 16
244 <211> LENGTH: 8
245 <212> TYPE: PRT
246 <213> ORGANISM: Artificial Sequence
248 <220> FEATURE:
249 <223> OTHER INFORMATION: Synthetic peptide sequence
251 <400> SEQUENCE: 16
253 Cys Trp Thr Trp Glu Thr Cys Glu
254 1               5
257 <210> SEQ ID NO: 17
258 <211> LENGTH: 16
259 <212> TYPE: PRT
260 <213> ORGANISM: Artificial Sequence
262 <220> FEATURE:
263 <223> OTHER INFORMATION: Synthetic peptide sequence
265 <400> SEQUENCE: 17
267 Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Thr Cys Glu Arg Gly Glu
268 1               5                   10                  15
271 <210> SEQ ID NO: 18
272 <211> LENGTH: 18
273 <212> TYPE: PRT
274 <213> ORGANISM: Artificial Sequence
276 <220> FEATURE:
277 <223> OTHER INFORMATION: Synthetic peptide sequence
279 <400> SEQUENCE: 18
281 Glu Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Thr Cys Glu Arg Gly
282 1               5                   10                  15
285 Glu Gly
289 <210> SEQ ID NO: 19
290 <211> LENGTH: 24
291 <212> TYPE: PRT
292 <213> ORGANISM: Artificial Sequence
294 <220> FEATURE:
295 <223> OTHER INFORMATION: Synthetic peptide sequence
297 <400> SEQUENCE: 19
299 Glu Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Thr Cys Glu Arg Gly
300 1               5                   10                  15
303 Glu Gly Gly Gly Gly Ser Gly Gly
```

304   20   .
307 <210> SEQ ID NO: 20
308 <211> LENGTH: 13
309 <212> TYPE: PRT
310 <213> ORGANISM: Artificial Sequence
312 <220> FEATURE:
313 <223> OTHER INFORMATION: Synthetic peptide sequence
315 <400> SEQUENCE: 20
317 Cys Trp Thr Trp Glu Thr Cys Glu Arg Gly Glu Gly Gln
318 1   5   10
321 <210> SEQ ID NO: 21
322 <211> LENGTH: 16
323 <212> TYPE: PRT
324 <213> ORGANISM: Artificial Sequence
326 <220> FEATURE:
327 <223> OTHER INFORMATION: Synthetic peptide sequence
329 <400> SEQUENCE: 21
331 Glu Val Trp Glu Val Leu Cys Thr Asp Trp Glu Ser Cys Glu Trp Gly
332 1   5   10   15
335 <210> SEQ ID NO: 22
336 <211> LENGTH: 13
337 <212> TYPE: PRT
338 <213> ORGANISM: Artificial Sequence
340 <220> FEATURE:
341 <223> OTHER INFORMATION: Synthetic peptide sequence
343 <400> SEQUENCE: 22
345 Trp Glu Val Leu Cys Met Asp Trp Glu Thr Cys Glu Arg
346 1   5   10
349 <210> SEQ ID NO: 23
350 <211> LENGTH: 15
351 <212> TYPE: PRT
352 <213> ORGANISM: Artificial Sequence
354 <220> FEATURE:
355 <223> OTHER INFORMATION: Synthetic peptide sequence
357 <400> SEQUENCE: 23
359 Glu Glu Trp Glu Val Leu Cys Trp Thr Trp Glu Thr Cys Glu Arg
360 1   5   10   15
363 <210> SEQ ID NO: 24
364 <211> LENGTH: 13
365 <212> TYPE: PRT
366 <213> ORGANISM: Artificial Sequence
368 <220> FEATURE:
369 <223> OTHER INFORMATION: Synthetic peptide sequence
371 <400> SEQUENCE: 24
373 Trp Lys Val Leu Cys Ala Thr Trp Ala Thr Cys Gln Arg
374 1   5   10
377 <210> SEQ ID NO: 25
378 <211> LENGTH: 13
379 <212> TYPE: PRT

```
<210>  101
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is absent or 1-100 amino acids

<220>
<221>  DISULFID
<222>  (2)..(2)

<220>
<221>  MISC_FEATURE
<222>  (3)..(7)
<223>  Xaa is any amino acid

<220>
<221>  DISULFID
<222>  (8)..(8)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is absent or 1-100 amino acids

<400>  101

Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa
1               5
```

variable length not permitted (see item 5 on Error summary sheet)

same error

This error also appears in Sequences 103 and 109

```
<210>  106
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide
```

← insufficient explanation (give source of genetic material)

see item 11 on Euro
summary
sheet

RAW SEQUENCE LISTING ERROR SUMMARY   DATE: 01/06/2006
PATENT APPLICATION: US/10/639,076A   TIME: 12:49:50

Input Set : A:\Sequence Listing.txt
Output Set: N:\CRF4\01062006\J639076A.raw

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220>
to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:101; Xaa Pos. 1,3,4,5,6,7,9
Seq#:102; Xaa Pos. 1,2,3,4,5,6,8,9,10,11,12,14,15,16,17,18
Seq#:103; Xaa Pos. 1,3,5
Seq#:104; Xaa Pos. 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20
Seq#:105; Xaa Pos. 1,2,3,4,6,7,10,11,12,13,15,16,17,18
Seq#:106; Xaa Pos. 1,5,8,11,13,14,15,16,17,18
Seq#:107; Xaa Pos. 1,5,8,11,13
Seq#:108; Xaa Pos. 1,2,3,7,10,13,15,16,17,18,19,20
Seq#:109; Xaa Pos. 1,2,3,4,5,6,8,9,10,11,12,14

Input Set : **A:\Sequence Listing.txt**
Output Set: **N:\CRF4\01062006\J639076A.raw**

```
L:1752 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:101 after pos.:0
L:1827 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:102 after pos.:0
M:341 Repeated in SeqNo=102
L:1862 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:103 after pos.:0
L:1882 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:104 after pos.:0
M:341 Repeated in SeqNo=104
L:1921 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:105 after pos.:0
M:341 Repeated in SeqNo=105
L:1965 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:106 after pos.:0
M:341 Repeated in SeqNo=106
L:2009 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:107 after pos.:0
L:2049 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:108 after pos.:0
M:341 Repeated in SeqNo=108
L:2103 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:109 after pos.:0
```